^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ROCK inhibitor

    Related drugs:
    Associations

    News

    Trials
    3d
    A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026
    Trial completion date
    |
    rovadicitinib (TQ05105)
    4d
    Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer. (PubMed, Cancer Res)
    Treatment with fasudil, a Rho kinase inhibitor, effectively blocked mitochondrial transfer and restored sensitivity to the EGFR-TKI osimertinib in vivo. Together, this work reveals targetable stromal-tumor crosstalk that sustains DTP populations, proposing a combination therapy for overcoming EGFR-TKI resistance.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • RHOA (Ras homolog family member A) • CCL11 (C-C Motif Chemokine Ligand 11)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib)
    10d
    The effects of baicalin on blood lipid metabolism and immune function in rats with gestational diabetes mellitus based on RhoA/ROCK pathway (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
    GDM rats were randomly divided into a model group, a fasudil (FA) (RhoA/RocK inhibitor) group (10 mg/kg), low-dose (100 mg/kg) and high-dose (200 mg/kg) baicalin groups, and a high-dose baicalin combined with LPA (RhoA/RocK activator) group (200 mg/kg baicalin+1 mg/kg LPA ), with 12 rats in each group...LPA could obviously weaken the improvement effects of baicalin on blood lipid metabolism and immune function in GDM rats. Conclusion Baicalin may improve blood lipid metabolism and immune function in GDM rats by inhibiting the RhoA/ROCK pathway.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • RHOA (Ras homolog family member A) • ROCK1 (Rho Associated Coiled-Coil Containing Protein Kinase 1)
    12d
    A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) (clinicaltrials.gov)
    P3, N=110, Completed, Kowa Research Institute, Inc. | Active, not recruiting --> Completed
    Trial completion
    18d
    GLR305-E001: Next Generation Rocklatan (clinicaltrials.gov)
    P2, N=426, Completed, Alcon Research | Active, not recruiting --> Completed
    Trial completion
    18d
    Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (clinicaltrials.gov)
    P4, N=35, Recruiting, Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment (clinicaltrials.gov)
    P1/2, N=48, Recruiting, Massachusetts Eye and Ear Infirmary | Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment open • Trial completion date • Trial primary completion date
    2ms
    Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (clinicaltrials.gov)
    P4, N=35, Not yet recruiting, Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
    New P4 trial
    3ms
    Ginsenoside Rc Targets ROCK2 to Inhibit NF-κB Activation and Alleviate Cognitive Dysfunction in Septic Encephalopathy in vitro and in vivo. (PubMed, Appl Biochem Biotechnol)
    GRc treatment effectively reduced ROCK2 expression and suppressed the secretion of inflammatory cytokines. These findings elucidate the pathological role of the ROCK2/NF-κBp65 signaling axis in SE and provide compelling evidence that GRc mitigates SE, at least in part, by directly binding to ROCK2 and inhibiting NF-κBp65 phosphorylation.
    Preclinical • Journal
    |
    ROCK2 (Rho Associated Coiled-Coil Containing Protein Kinase 2)
    3ms
    Rocklatan Retinal Perfusion OCT Study (clinicaltrials.gov)
    P4, N=30, Not yet recruiting, Oregon Health and Science University
    New P4 trial
    3ms
    LncRNA BASP1-AS1 Drives PCBP2 K115 Lactylation to Suppress Ferroptosis and Confer Oxaliplatin Resistance in Gastric Cancer. (PubMed, Free Radic Biol Med)
    Concurrently, BASP1-AS1-mediated histone H3K14 lactylation transcriptionally upregulates both LDHA and PCBP2, generating a self-amplifying metabolic-epigenetic circuit. This axis critically suppresses ferroptosis and maintains chemoresistance, providing actionable targets for overcoming oxaliplatin resistance in GC.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • BASP1 (Brain Abundant Membrane Attached Signal Protein 1)
    |
    oxaliplatin
    3ms
    Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (clinicaltrials.gov)
    P3, N=470, Recruiting, Alcon Research | Not yet recruiting --> Recruiting
    Enrollment open